Accepting the Protocol

Part of Principal Investigator (PI) Training: Signatures and What They Attest.

About 4 minutes. Free, in your language, no account needed.

Why this matters

The protocol signature page is usually presented as the last item in a start-up pack, somewhere between the laboratory manual and the shipping addresses. It is not administrative. It is the moment you take personal responsibility for conducting a study exactly as written, at a site you have not yet tested, for participants you have not yet met.

Nearly every protocol-compliance finding in clinical research traces back to a signature given before the document was properly read.

What the signature commits you to

Section 2.5.1 requires the investigator's agreement to the protocol to be documented — by signing the protocol, or through an alternative contractual arrangement. Section 2.5.2 then states the obligation that signature creates: conduct the trial in compliance with the protocol agreed with the sponsor and, as required, approved by the IRB or IEC, and in compliance with GCP and applicable regulatory requirements.

Put plainly, your signature says three things:

1. I have read this protocol and I understand what it requires.
2. My site can do all of it, on these participants, for this duration.
3. I will not change it unilaterally.

The third is the one that bites. Once signed, a protocol is not adaptable to local convenience. A visit window is not a suggestion. A prohibited concomitant medication is not negotiable because the participant is already on it.

Reading a protocol as the investigator

You are not reading for the same things a coordinator reads for. Six passes, and none of them is the whole document from front to back.

• Objectives and endpoints. What question is this trial actually answering? If you cannot say it in a sentence, you cannot consent anyone properly and you cannot judge later whether a deviation matters.
• Eligibility criteria, one line at a time. For each criterion, ask: can I assess this at my site, with the equipment and turnaround times I actually have? A criterion requiring a result within 48 hours from a laboratory with a five-day turnaround is a deviation already scheduled.
• The safety sections. Dose modification rules, stopping rules, the reference safety information, the definitions of expected events, and what the protocol exempts from immediate reporting.
• The schedule of assessments. Count the participant's time, not yours. A schedule that demands nine hours on day one will produce withdrawals in month two.
• The prohibited and permitted medications. Against your actual population. An exclusion of a common drug class in a comorbid population may cut your recruitment estimate in half.
• What it asks you to do personally. Some protocols require investigator-performed assessments, investigator signature on eligibility, or investigator presence at first dose. Find these before you agree to them.

Say it before you sign it

If a requirement will not work at your site, the time to say so is during feasibility, when a protocol can be clarified, a country-specific appendix can be written, or you can decline. After signature, the same conversation is a deviation report.

Two questions worth asking the sponsor explicitly before signing:

• Which deviations does this sponsor consider important, and how do they want them reported?
• What exactly are the data endorsement milestones under §2.12.5, and what will you be asking me to sign?

Both answers are easy to get at start-up and awkward to get in month eight.

Approval before conduct

One sequence is absolute. Written, dated approval or favorable opinion from the IRB or IEC precedes the start of the trial, and the same applies to amendments and to participant-facing material (§2.4). No screening, no consent, no trial-specific procedure before it exists. There is a single narrow exception, and it is the deviation to eliminate an immediate hazard to a participant under §2.5.4 — covered in Module 8.

Key takeaways

• §2.5.1: your agreement to the protocol is documented by signature or contract; §2.5.2 makes it an obligation to comply.
• Read as the investigator: objectives, eligibility feasibility, safety rules, participant burden, medication conflicts, and what the protocol asks of you personally.
• Raise unworkable requirements during feasibility. After signature the same conversation becomes a deviation.
• IRB/IEC written approval precedes any trial conduct, with only the immediate-hazard exception.